BIOMARIN PHARMACEUTICAL INC
Nasdaq: BMRN·San Rafael, California·CIK 0001048477
- Price
- $57.99
- Base IV
- $91.93
Valuation snapshot
At $57.99, the price sits between our bear case ($41.29) and base case ($91.93).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $91.93
- above today's price · range $41.29–$186.24
- Price vs base case
- 37% below
- $57.99 against $91.93
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $41.29 to bull $186.24. Values per share.
Price against each value
- Bear case
- $41.29
- Price 40% above
- No growth
- …
- —
- Base case
- $91.93
- Price 37% below
What does Biomarin Pharmaceutical do?
BioMarin Pharmaceutical provides medicines and enzyme therapies for patients with genetically defined rare diseases, such as achondroplasia and mucopolysaccharidosis.
It brought in $3.7B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- San Rafael, California
- Trades on
- Nasdaq as BMRN
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.01, so it lost 1¢ on each dollar. The biggest cost is sales, marketing and admin, 39¢ of every dollar.
- Making what it sells24¢
- Research and development21¢
- Sales, marketing and admin39¢
- Everything else it takes to operate13¢
- Interest and other costs2¢
- Tax2¢
- Lost on each dollar−1¢
Who pays Biomarin Pharmaceutical, and for what?
BioMarin Pharmaceutical develops and sells specialized biopharmaceutical therapies for people with serious and life-threatening rare genetic diseases. It makes money primarily by marketing proprietary commercial enzyme therapies and skeletal disease treatments directly and through specialty distributors to healthcare providers worldwide.
Customers include specialty pharmacies, hospitals, government health agencies, authorized distributors, and pharmaceutical wholesalers.
VOXZOGO
29%Daily injection therapy for achondroplasia, the most common form of disproportionate short stature.
VIMIZIM
25%Enzyme replacement therapy for treating Mucopolysaccharidosis IVA (MPS IVA), a lysosomal storage disorder.
NAGLAZYME
15%Recombinant enzyme replacement therapy for patients suffering from Mucopolysaccharidosis VI (MPS VI).
PALYNZIQ
13%Subcutaneous injectable enzyme therapy that reduces blood phenylalanine concentrations in patients with phenylketonuria.
ALDURAZYME
6%Enzyme therapy for MPS I developed and commercialized worldwide in collaboration with Sanofi.
BRINEURA
6%Recombinant enzyme infusion designed to slow the loss of walking ability in children with CLN2 disease.
Where its work physically happens, beyond headquarters:
- Novato Manufacturing Campus (Galli Drive) — Novato, United States. BioMarin's roughly 292,300 sq ft of owned Novato facilities make the active ingredient for Aldurazyme, Naglazyme, Palynziq and Voxzogo, which concentrates single-site supply risk, and a September 2026 consolidation into a smaller site could move some of that production.
- Shanbally Manufacturing Facility — Shanbally, Ireland. This owned 260,700 sq ft plant is BioMarin's only disclosed manufacturing site outside the U.S., making the active ingredient for Brineura and Vimizim and providing aseptic filling and packaging capability that diversifies supply away from Novato.
- Philadelphia Office and Laboratory (Amicus) — Philadelphia, United States. This 50,816 sq ft leased site, the largest in Amicus's FY2025 property table with a lease running to September 2034, came with the April 2026 Amicus acquisition, though its role under BioMarin's post-deal restructuring is not yet disclosed.
- Marlow Office (Amicus) — Marlow, United Kingdom. This 36,796 sq ft leased office, acquired with Amicus on a lease expiring August 2028, is the largest non-U.S. office in Amicus's FY2025 property table and gives BioMarin a UK base for the acquired business, subject to integration decisions.
How is the business doing?
Sales grew from $1.9B in 2020 to $3.2B in 2025, about 12% a year.
Running the business leaves about 3¢ of each sales dollar as operating profit, up from 2¢ in 2020.
After paying for its upkeep and new investment, it had $557.9M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
BioMarin seeks to harness genetic science to develop innovative, life-changing medicines for people with rare diseases.
“Patients are our purpose. Science is our passion.”
What management says it is working on now:
Closing and Integrating Amicus Acquisition
Completing the planned $4.8 billion acquisition of Amicus Therapeutics to add commercial treatments for Fabry and Pompe diseases.
BioMarin Pharmaceutical Inc. 2025 Form 10-KExpanding VOXZOGO Indications
Advancing clinical trials for VOXZOGO beyond achondroplasia to treat conditions such as hypochondroplasia and idiopathic short stature.
BioMarin Pharmaceutical Inc. 2025 Form 10-KCost Transformation and Portfolio Assessment
Prioritizing high-value R&D assets while withdrawing underperforming programs, including the market exit from gene therapy ROCTAVIAN.
BioMarin Pharmaceutical Inc. 2025 Form 10-KAdvancing Late-Stage Clinical Pipeline
Developing acquired pipeline therapies including BMN 401 for ENPP1 deficiency, BMN 333, and BMN 351 for Duchenne muscular dystrophy.
BioMarin Pharmaceutical Inc. 2025 Form 10-K
- Total revenues, Full-Year 2026
- $3,325 million to $3,425 million
- BioMarin Reports Fourth Quarter and Full-Year 2025 Financial Results
- Enzyme Therapies revenue, Full-Year 2026
- $2,225 million to $2,275 million
- BioMarin Reports Fourth Quarter and Full-Year 2025 Financial Results
- VOXZOGO revenue, Full-Year 2026
- $975 million to $1,025 million
- BioMarin Reports Fourth Quarter and Full-Year 2025 Financial Results
- Non-GAAP diluted EPS, Full-Year 2026
- $4.95 to $5.15
- BioMarin Reports Fourth Quarter and Full-Year 2025 Financial Results
What's changing right now?
Growth is picking up. In Q3 2026 it sold 32% more than a year earlier. The year before, quarters averaged 11%.
Its operating margin is narrower than a year ago: a loss of 8¢ per sales dollar, against a loss of 6¢.
The share price is about where it was in Oct 2026, near $57.99.
Recently
February 25, 2026
Annual Research and Development Expense changed to $921.9M
BioMarin Pharmaceutical Inc. Form 10-K for the Year Ended December 31, 2025February 25, 2026
Voxzogo Annual Net Product Revenue changed to $926.9M
BioMarin Pharmaceutical Inc. Form 10-K for the Year Ended December 31, 2025
Coming up
Second Quarter 2026
Closing of Amicus Therapeutics Acquisition
Completion of the $4.8 billion cash acquisition of Amicus Therapeutics, expanding BioMarin's rare disease commercial portfolio.
BioMarin Pharmaceutical Inc. 2025 Form 10-K2026
VOXZOGO Phase 3 Readout in Hypochondroplasia
Pivotal Phase 3 clinical trial readout and anticipated regulatory filings to expand VOXZOGO to treat hypochondroplasia.
BioMarin Pipeline Updates2026-2027
BMN 401 Clinical Program Milestones
Advancing clinical readouts and regulatory steps for BMN 401 for ENPP1 deficiency following the Inozyme acquisition.
BioMarin Pharmaceutical Inc. 2025 Form 10-KPrior to or concurrently with Amicus closing in 2026
Senior Secured Credit Facilities Execution
Entering into a $2.8 billion term loan and $600 million revolving facility to replace the bridge loan for the Amicus purchase.
BioMarin Pharmaceutical Inc. 2025 Form 10-K
Our own estimate moved too: the base case went from $74.88 to $91.93 a share between our last two valuations. The biggest reason: Voxzogo Annual Net Product Revenue moved from an unreported prior value to $926.9M, as reported in BioMarin Pharmaceutical Inc. Form 10-K for the Year Ended December 31, 2025.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Third-Party Reimbursement and Pricing Pressure
Because treatments target small populations and carry high per-patient prices, any cuts to insurance or government reimbursement harm sales.
From the company's own filingsWould hit how fast sales growBioMarin Pharmaceutical Inc. 2025 Form 10-K
Amicus Acquisition Integration and Debt Burden
Taking on billions in debt to fund the Amicus acquisition could strain cash flows if the integration encounters regulatory or operational delays.
From the company's own filingsWould hit how much of each sale it keepsBioMarin Pharmaceutical Inc. 2025 Form 10-K
Emerging Competition for Key Therapies
Rival biotechnology firms are advancing clinical candidates for achondroplasia and rare enzyme disorders that may challenge VOXZOGO.
From the company's own filingsWould hit how fast sales growBioMarin Pharmaceutical Inc. 2025 Form 10-K
Generic Erosion of Mature Products
Generic versions of KUVAN have already decreased sales, and future patent expirations across other franchises could invite generic competitors.
From the company's own filingsWould hit how fast sales growBioMarin Pharmaceutical Inc. 2025 Form 10-K
Lumpy Ordering and Customer Concentration
Three customers generated 37% of product sales in 2025, and irregular bulk orders from foreign governments create quarter-to-quarter revenue swings.
From the company's own filingsWould hit how fast sales growBioMarin Pharmaceutical Inc. 2025 Form 10-K
Clinical Trial and Regulatory Approval Risks
Developing biopharmaceuticals is costly and uncertain; failure to hit trial endpoints or secure regulatory approvals will disrupt expected growth.
From the company's own filingsWould hit how much it has to reinvestBioMarin Pharmaceutical Inc. 2025 Form 10-K
Order timing delays and international shipment volatility impacted third-quarter 2026 revenue growth.
From our researchWould hit how fast sales growBioMarin Q3 2026 Financial Release
GAAP operating margins remain subject to episodic IPR&D and restructuring write-downs, as seen in Q3 2026 (-8.0%).
From our researchWould hit how much of each sale it keepsBioMarin Q3 2026 Form 10-Q
Is it a good business?
From 2016 to 2025 it earned between -22% and 8% on the capital invested in it, a median of -1%. Its cost of capital in the latest valuation is 6.4%; returns were above it in 1 of the 10 years.
From 2016 to 2025 it earned between -23% and 21% on its shareholders' equity, a median of 1%.
Over 10 years its operating margin ranged from 72¢ to 17¢ per sales dollar, a median of 2¢. Gross margin ran from 72¢ to 82¢.
Cost of capital 6.4%
The number of shares has held roughly steady over the past year.
It owes $3.4B more than it holds in cash, about 30.2 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $57.99. Our put its value between $41.29 and $186.24, with $91.93 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $41.29
After steady revenue expansion to over three billion dollars, this scenario envisions sales growth slowing as flagship bone-growth drug Voxzogo faces emerging rivals and manufacturing overhead caps company profitability.
Base case, $91.93
Building on consistent double-digit revenue gains reaching over three billion dollars, this scenario anticipates steady global adoption of key pediatric treatments paired with disciplined cost reductions that expand long-term profit margins.
Bull case, $186.24
Following an acceleration toward nearly four billion dollars in annual sales, this scenario models rapid global adoption of core therapies across newly approved indications alongside major production efficiencies that lift business profitability to peak levels.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects less than we do.Margin of safety: 37%
At today's $57.99, the price makes sense if sales shrink about 0.3% a year. We assume they grow 7.8%. Over the last 5 years, sales grew 14.6% a year.
Or, if sales grow 7.8% as we assume, the price works with a profit margin of 18.0% (we assume 26.0%).
Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.
Do you think sales will shrink?
Try your own numbersWe're not very sure of this range: it scores 49 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $91.93 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average7.8%
- Operating margin26.0%
- Long-term growth rate2.8%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$91.93 58.5%


